Abstracts tagged "lupus-like disease"

Abstract Number: 0898 • ACR Convergence 2023
The Role of the Endothelin System in the Development of TLR7-accelerated Lupus-Associated Cardiac Dysfunction
Kennedy Hawkins, Marice McCrorey, C. Alex Colvert, Kristine DeLeon-Pennell, Melissa Cunningham and Justin Van Beusecum, Medical University of South Carolina, Charleston, SC
Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune disease characterized by autoantibody formation and immune complex deposition in target organs. While it is known that…
Abstract Number: 0920 • ACR Convergence 2023
Proinflammatory Neutrophils and NETs Mediate Skin and Kidney Inflammation During Lupus Flare in Asymptomatic Lupus-prone Mice Triggered by UVB
Xing Lyu¹, minghui li¹, ping zhang², Wei Wei³, victoria werth⁴ and Ming-Lin Liu⁵, ¹Tianjin Medical University, Tianjin, China, ²Beaumont Hospital Royal Oak, Royal Oak, MI, ³Tianjin Medical University General Hospital, Tianjin, China, ⁴University of Pennsylvania, Wynnewood, PA, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: Ultraviolet B (UVB) exposure triggers lupus flare by worsening both skin lesions and systemic symptoms, i.e. lupus nephritis. We recently reported that UVB exposure…
Abstract Number: 0922 • ACR Convergence 2023
The Multi-Omic Landscape of Systemic Lupus Erythematosus Patients Highlights Metabolic and Immune Pathways Associated with Distinctive Clinical Profiles
Tomás Cerdó¹, Carlos Perez-Sanchez², Laurel Woodridge³, Mª Angeles Aguirre⁴, Rafaela Ortega Castro⁵, Ismael Sánchez-Pareja⁶, Laura Muñoz-Barrera¹, Pedro Segui¹, Christian Merlo⁶, Pedro Ortiz Buitrago⁷, Desiree Ruiz Vilchez⁸, Maria del Carmen Abalos-Aguilera⁸, Pilar Font Ugalde¹, Nuria Barbarroja⁹, Alejandro Escudero¹⁰, Elizabeth Jury³ and Chary Lopez-Pedrera¹¹, ¹IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ²IMIBIC, Córdoba, Spain, ³Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom, ⁴Reina Sofía University Hospital/ Rheumatology Department, Córdoba, Spain, ⁵Hospital Reina Sofía, Cordoba, Spain, ⁶IMIBIC/Reina Sofia Hospital/University of Cordoba, Rheumatology, Córdoba, Spain, ⁷IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁸Rheumatology Department, Reina Sofia University Hospital/Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Córdoba, Spain, ⁹University of Cordoba, Córdoba, Spain, ¹⁰SAS, Córdoba, Spain, ¹¹IMIBIC - Reina Sofia Hospital, Córdoba, Spain
Background/Purpose: Systemic lupus erythematosus (SLE) poses a significant challenge at the diagnostic and treatment levels due to its severe multisystem nature and notable heterogeneity in…
Abstract Number: 1491 • ACR Convergence 2023
Targeting the Mevalonate Pathway-dependent Protein Geranylgeranylation to Restrict Follicular Helper T Cell Differentiation for the Treatment of Systemic Lupus Erythematosus
Lai Wang, Institute of Dermatology, Chinese Academy of Medical Sciences and Peking Union Medical College, Nanjing, China
Background/Purpose: Recent research focusing on follicular helper T (Tfh) cells emphasizes its importance in autoimmune diseases, such as systemic lupus erythematosus (SLE). However, the mechanisms…
Abstract Number: 1732 • ACR Convergence 2022
Novel Human Class II MHC Tetramers Detect Rare, Self-Reactive CD4+ T Cells Relevant to Mixed Connective Tissue Disease
Shawn Mahmud, Thamotharampillai Dileepan, Bryce Binstadt and Marc Jenkins, University of Minnesota, Minneapolis, MN
Background/Purpose: Nearly all patients with mixed connective tissue disease (MCTD) have IgG autoantibodies (autoAb) specific for U170k, a component of the U1-snNRP spliceosomal complex. A…
Abstract Number: PP14 • ACR Convergence 2022
The Use of Social Support as Treatment
Aleta McLean, Open Hand Atlanta, Atlanta, GA
Background/Purpose: The months leading up to my diagnosis were frustrating. Initially my hair started falling out. I was told it was stress related. I was…
Abstract Number: 0662 • ACR Convergence 2022
Partial Correlations Network Models Show Th1, Th2 and Th17 Responses to Be Interlinked in Dermal Pathogenesis of Cutaneous Lupus Erythematous
Felix Chin¹, Thomas Vazquez², Josh Dan³, DeAnna Diaz⁴, Grant Sprow⁵, Jay Patel⁶, Nilesh Kodali⁷, Rui Feng⁸ and Victoria Werth⁹, ¹University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ²FIU Wertheim College of Medicine, Virginia Beach, VA, ³Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ⁴Philadelphia College of Medicine, Philadelphia, PA, ⁵Albert Einstein College of Medicine, Philadelphia, PA, ⁶Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PN, ⁷New Jersey Medical School, Coppell, TX, ⁸University of Pennsylvania, Philadelphia, ⁹University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
Background/Purpose: The immunopathogenesis of cutaneous lupus erythematous (CLE) is highly diverse and involves activity of many different cell types and pathways. This heterogeneity is believed…
Abstract Number: 0667 • ACR Convergence 2022
Correlation Matrices Visualize Differential Degree of Cell and Pathway Heterogeneity in Skin of Cutaneous Lupus Erythematosus Treatment Subgroups
Felix Chin¹, Thomas Vazquez², Josh Dan³, DeAnna Diaz⁴, Grant Sprow⁵, Jay Patel⁶, Nilesh Kodali⁷, Rui Feng⁸ and Victoria Werth⁹, ¹University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ²FIU Wertheim College of Medicine, Virginia Beach, VA, ³Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ⁴Philadelphia College of Medicine, Philadelphia, PA, ⁵Albert Einstein College of Medicine, Philadelphia, PA, ⁶Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PN, ⁷New Jersey Medical School, Coppell, TX, ⁸University of Pennsylvania, Philadelphia, ⁹University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
Background/Purpose: First-line treatment for cutaneous lupus erythematosus involves the use of antimalarials. Treatment response is highly variable with some patients responding well to hydroxychloroquine (HCQ),…
Abstract Number: 0795 • ACR Convergence 2022
Post-Acute COVID-19 Sequalae (PACS) with New-onset Rheumatological Complications
Neel Thanavala¹, Kiho Son², Nardien Sedhom², Snehal Somalwar³, Zil Patel¹, Rameen Jamil², Carmen Venegas², Ashutosh Thakar², Agnes Yuen⁴, Melanie Kjarsgaard², Susan Waserman², Mylinh Duong², Parameswaran Nair², Christopher Carlsten⁴, Maggie Larche², Terence Ho², Sarah Svenningsen², KONSTANTINOS TSELIOS⁵ and Manali Mukherjee², ¹The Research Institute of St. Joe's Hamilton, Hamilton, ON, Canada, ²McMaster University, Hamilton, ON, Canada, ³The Research Institute of St Joe's Hamilton, Hamilton, ON, Canada, ⁴University of British Columbia, Vancouver, BC, Canada, ⁵McMaster University, Population Health Research Institute, Hamilton, ON, Canada
Background/Purpose: Post-Acute Sequalae of COVID-19 (PASC), prevalent in ~20-30% of convalescent COVID-19 patients is characterized by new/persistent symptoms after the initial recovery. Certain autoantibodies have…
Abstract Number: 1484 • ACR Convergence 2022
Management of the Heightened Risk for Clinical Events from Atherosclerotic Cardiovascular Disease (ASCVD) in an Established Cohort of Lupus Erythematosus Patients
Megan Zhao¹, Kevin Williams², Douglas Jacoby³, Rui Feng⁴ and Victoria Werth⁵, ¹Perelman School of Medicine, Philadelphia, ²Temple University Hospital System, Philadelphia, ³University of Pennsylvania Health System, Philadelphia, ⁴University of Pennsylvania, Philadelphia, ⁵Philadelphia VAMC, Philadelphia, PA, USA and Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia
Background/Purpose: Lupus erythematosus (LE) patients are at heightened risk of clinical events, chiefly heart attacks and strokes, caused by ASCVD. To address this problem, we…
Abstract Number: 1689 • ACR Convergence 2022
Oral Ginger Supplementation Counteracts NETosis in Autoimmune Mouse Models and in Healthy Humans
Ramadan Ali¹, Miela Zahavi², Christine Rysenga¹, Cyrus Sarosh³, Claire Hoy¹, Kristen Demoruelle⁴ and Jason S Knight⁵, ¹University of Michigan, Ann Arbor, MI, ²Universtiy of Michigan, Ann Arbor, MI, ³University of Michigan, Temperance, MI, ⁴University of Colorado Anschutz Medical Campus, Aurora, CO, ⁵University of Michigan, Division of Rheumatology, Ann Arbor, MI
Background/Purpose: It has previously been reported that 6-gingerol, the most abundant phytochemical in ginger root, inhibits neutrophil phosphodiesterase activity and thereby counteracts neutrophil hyperactivity in…
Abstract Number: 1721 • ACR Convergence 2022
Protective Effects of the Natural Antioxidant Taxifolin in Models of Lupus and Antiphospholipid Syndrome
Christine Rysenga¹, Linda May-Zhang², Miela Zahavi³, Jason S Knight⁴ and Ramadan Ali¹, ¹University of Michigan, Ann Arbor, MI, ²Blue California, Rancho Santa Margarita, CA, ³Universtiy of Michigan, Ann Arbor, MI, ⁴University of Michigan, Division of Rheumatology, Ann Arbor, MI
Background/Purpose: Taxifolin, also known as dihydroquercetin, is a bioactive flavonoid commonly found in apples, onions, French maritime bark, and milk thistle. Given its potent anti-inflammatory…
Abstract Number: 0537 • ACR Convergence 2021
The Clinical, Oral Small Molecule IRAK4 Inhibitor, GS-5718, Improves Survival and Reduces Disease Pathologies by Modulating Multiple Inflammatory Endpoints in the Murine NZB/W Model of Spontaneous Lupus
Adam Yadon¹, Vanessa Gorney², Angie Hammond³, Ethan Grant² and Astrid Clarke³, ¹Gilead Sciences, Inc., Seattle, WA, ²Gilead Sciences, Inc, Foster City, CA, ³Gilead Sciences, Inc, Seattle, WA
Background/Purpose: Lupus is a heterogenous autoimmune disease characterized by loss of immune tolerance, production of nucleic acid:autoantibody immune complexes, immune cell hyperactivation, and increased proinflammatory…
Abstract Number: 0539 • ACR Convergence 2021
Vgll3-transgenic Autoimmune Mice Display Features of Cutaneous Fibrosis
Mehrnaz Gharaee-Kermani¹, Allison Billi², Marisa Hildebrandt², Jacob Martens³, Rachael Wasikowski², Joanne (Michelle) Kahlenberg¹ and Johann Gudjonsson², ¹Internal Medicine - Division of Rheumatology and Department of Dermatology, University of Michigan, Ann Arbor, MI, ²Department of Dermatology, University of Michigan, Ann Arbor, MI, ³Graduate Program in Immunology, University of Michigan, Ann Arbor, MI, USA, Ann Arbor, MI
Background/Purpose: Fibrosis is characterized by collagen deposition, fibro/myofibroblast accumulation, and extracellular matrix remodeling and can lead to disfiguring skin changes. In cutaneous lupus, scar formation…
Abstract Number: 0436 • ACR Convergence 2020
The Addressing Lupus Pillars for Health Advancement (ALPHA) Project: Establishing Consensus and Prioritization of Global Community Recommendations to Address Major Challenges in Lupus Diagnosis, Care, Treatment and Research
Karin Tse¹, Sanjyot Sangodkar², Kathleen Arntsen³, Sang-Cheol Bae⁴, Lauren Bloch², Ian Bruce⁵, Erin Connolly-Strong⁶, Karen Costenbader⁷, Thomas Dörner⁸, Sydney Evans⁹, Timothy Franson², Kenneth Getz¹⁰, Amy Kao¹¹, Kenneth Kalunian¹², Bradley Dickerson¹³, Susan Manzi¹⁴, Eric Morand¹⁵, Yaritza Peña¹⁰, Sandra Raymond¹⁶, Brad Rovin¹⁷, Laura Schanberg¹⁸, Joan Von Feldt¹⁹, Victoria Werth²⁰, Angel Williams²¹, David Zook² and Leslie Hanrahan¹⁶, ¹Lupus Foundation of America, DC, WA, ²Faegre Drinker Consulting, Washington, DC, ³Lupus and Allied Diseases Association, Inc., Verona, NY, ⁴Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁵Centre for Epidemiology Versus Arthritis, The University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ⁶Mallinckrodt, Austin, TX, ⁷Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁸DRFZ and Charité University Hospitals, Berlin, Germany, ⁹Lupus Patient Representative, Riverdale, MD, ¹⁰Tufts Center for the Study of Drug Development, Boston, MA, ¹¹EMD Serono (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ¹²University of California San Diego, La Jolla, CA, ¹³Aurinia Pharmaceuticals, Fort Washington, PA, ¹⁴Lupus Center of Excellence, Autoimmunity Institute, Allegheny Health Network, Pittsburgh, PA, ¹⁵Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia, ¹⁶Lupus Foundation of America, Washington, DC, ¹⁷The Ohio State University, Columbus, ¹⁸Duke University Medical Center, Durham, NC, ¹⁹GlaxoSmithKline, WILMINGTON, DE, ²⁰University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, ²¹Lupus Patient Representative, Richmond, VA
Background/Purpose: The Addressing Lupus Pillars for Health Advancement (ALPHA) Project is a global consensus effort to identify, prioritize and address top barriers in lupus impacting…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].